Skip to content
OpenCapital
Get started

OraSure Technologies OSUR HCV — Net revenues

Other product segments

HIV
$13.02M+0.9%
Sample Management Solutions
$9.06M-0.6%
Other Product And Services Revenues
$1.62M+109%
Non-product and services revenues
$1.55M+65.8%
COVID-19
$18K-96.1%
Risk Assessment Testing
$0-100%

Similar metrics at other companies

TFX
TFXVascular — Net revenues
$236.81M+8.1%
WD-40 Company logo
WDFCHCCP — Net Sales
$4.84M-28.7%
Gilead Sciences logo
GILDTotal HIV — Total revenues
$5.03B+9.7%
Gilead Sciences logo
GILDSofosbuvir/Velpatasvir — Total revenues
$283M-18.2%
Genpact logo
GConsumer and Healthcare — Net revenues
$446.31M+6.1%
Ligand Pharmaceuticals logo
LGNDCapvaxive — Total revenues and income
$1.97M+122%

Other financials

Income statement

See full
Revenue$27.9M-6.7%
Gross profit$11.8M-4.0%
Operating income-$23.3M-31.1%
Net income-$22.4M-39.5%
EPS (diluted)-$0.32-52.4%

Balance sheet

See full
Cash & equivalents$177.0M-28.5%
Total debt$12.7M-10.9%
Total equity$313.3M-20.9%
Total assets$379.2M-17.1%

Cash flow

See full
Operating cash flow-$13.9M+29.6%
CapEx$913.0K+117%
Free cash flow-$14.8M+26.5%

Valuation

See full
Market cap$303.62M+35.3%
Enterprise value$139.32M-1,654%
P/S2.7×+1.3×

Profitability

See full
Gross margin42.2%+0.4pp
Operating margin-68.6%-149pp
Net margin-66.4%-115pp
FCF margin-42.4%-43.3pp

Returns & leverage

See full
Return on equity-21.2%-50.4pp
Debt / equity0×0.0×
Current ratio5.5×-6.9×

Where this comes from

Reported directly by OraSure Technologies in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: OraSure Technologies’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about OraSure Technologies's hcv — net revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OraSure Technologies's HCV — net revenues?
OraSure Technologies (OSUR) reported HCV — net revenues of $2.66M in Q1 2026.
How has OraSure Technologies's HCV — net revenues changed year-over-year?
OraSure Technologies's HCV — net revenues decreased by 38.5% year-over-year, from $4.33M to $2.66M.
What does HCV — net revenues mean?
This metric represents the total gross sales generated from the Hepatitis C virus diagnostic and specimen collection product line after accounting for returns and allowances. It serves as a key indicator of the company's market penetration and demand for its infectious disease screening solutions within the diagnostics segment. Monitoring this revenue stream helps investors assess the commercial performance and growth trajectory of the company's specific portfolio of viral diagnostic tools.